precision medicine

Dr. David Spetzler

Caris Life Sciences Partners with Moderna To Advance mRNA-Based Cancer Drugs

by | Oct 24, 2023
Irving-based Caris said that via this multiyear agreement, Moderna will leverage Caris’ extensive library of de-identified, multimodal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses—along with claims data to improve development strategies for Moderna’s oncology pipeline.
MORE
Irving’s Caris Life Sciences Raises $830M to Grow Its Precision Medicine Platform for Cancer Care
by | May 12, 2021
Now valued at more than $7.8 billion, Caris specializes in AI-powered genetic sequencing for personalized cancer treatments. The massive capital raise follows a $310 million round in October and boosts the 13-year-old company's total funding to about $1.3 billion.
MORE
Caris Life Sciences Raises $310M to Continue Rapidly Growing in the Precision Medicine Market
by | Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE
genome
North Texas Genome Center Seen as Boon for Health Care, DFW Economy
by | Mar 2, 2018
The new center, on the campus of UT Arlington, will be available to academic and corporate researchers. Official said it could help elevate the region as a leader in precision medicine.
MORE